Scientists have discovered how skin cancer cells shapeshift based on their environment – enabling them to spread through the body and cause a metastatic cancer. The discovery of two genes responsible for sensing the environment and adapting cell shape could offer potential new drug targets to… Read More
Sharad Adekar, Medical Chair Lead and Currien MacDonald, Medical Chair Director at WCG, discuss the risks and benefits of using immunotherapies to treat cancer. In the last decade, a paradigm shift has occurred in the landscape of cancer treatment1. Supported by current advances in understanding of the mechanism and pathways… Read More
Nutcracker Therapeutics’ prostate cancer mRNA drug candidate NTX-470 successfully engaged CD3 T cells, while retaining low bystander activity and reduced off-tumour binding, according to data presented at the 2024 AACR Annual Meeting. There are limited treatment options for the 10-20% of prostate cancer patients who develop… Read More
Professor Shannon Westin is principal investigator of the DUO-E trial, here she speaks to DDW’s Megan Thomas about why the standard of care needs improving and the impact of therapeutic antibodies such as durvalumab. The DUO-E trial is a three-arm, randomised, double-blind, placebo-controlled, multicentre Phase III trial assessing the combination… Read More
DDW’s Megan Thomas speaks to Stefano Gullà, Chief Scientific Officer at Kling Biotherapeutics. MT: Where do you work, and can you tell us what you’re working on at the moment? SG: I am the Chief Scientific Officer at Kling Biotherapeutics. Together with my colleagues, I am tackling what is… Read More
On the final day of AACR, the plenary session of the Annual Meeting put artificial intelligence at the forefront and featured a stellar lineup of AI and data science experts who discussed AI and topics such as imaging, precision medicine, and drug development. The closing plenary… Read More
Today, National Cancer Institute leaders discussed cancer breakthroughs and the importance of securing support from lawmakers for the NCI and National Institutes of Health in the session ‘The Cancer Moonshot: Opportunities to Fulfill the Vision of the National Cancer Plan – Dedicated to the Memory of Sen. Dianne… Read More
A round-up of the latest news from the American Association of Cancer Research (AACR) Annual Meeting. Symposiums UCLA: Dr Zev Wainberg, Co-Director of the UCLA Health GI Oncology Program, presented results from pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators, which suggests that for… Read More
A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response. When tested in mice with non-small cell lung cancer (NSCLC), the team discovered… Read More
The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science. The session ‘Inspiring Science, Fueling Progress, Revolutionizing Care’ featured a distinguished panel of cancer… Read More
Researchers have shown for the first time that a crucial interface in a protein that drives cancer growth could act as a target for more effective treatments. The study was led by the Science and Technology Facilities Council (STFC) Central Laser Facility (CLF) and used advanced laser imaging techniques to… Read More
Curve Therapeutics’ CSO Ali Tavassoli has published an article in the Journal of the American Chemical Society (JACS) which highlights the potential of HIF inhibition as a therapeutic approach for cancers. The paper is titled ‘Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors (HIF) 1 and… Read More
Bio-Rad Laboratories has launched validated antibodies for rare cell and circulating tumour cell (CTC) enumeration for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits. The antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of… Read More
Scientists have discovered how breast cancer cells can ‘hibernate’ to avoid treatment and ‘wake up’ years later – causing a relapse that is more difficult to treat. Their research, published in the journal Cancer Discovery, reveals the role of epigenetics in controlling how cancer cells can… Read More
Cancer Research UK and the Norwegian Cancer Society (NCS) have announced a new multi-project strategic partnership to maximise the unique drug development capabilities of both countries. Under the partnership, NCS intends to share funding and expertise to accelerate the development of cancer drug candidates with the… Read More
Targeting two brain tumour-associated proteins – rather than one – with CAR-T cell therapy has shown promise as a strategy for reducing solid tumour growth in patients with recurrent glioblastoma (GBM). This is according to early results from the first six patients treated in an ongoing… Read More
